Dexamethasone in adults with bacterial meningitis

Area of Science:

• Infectious Diseases
• Neurology
• Critical Care Medicine

Background:

• Acute bacterial meningitis, particularly pneumococcal meningitis, is associated with high mortality and morbidity rates in adults.
• Adjuvant corticosteroid treatment has demonstrated beneficial effects in animal models of bacterial meningitis.

Purpose of the Study:

• To evaluate the efficacy of adjuvant dexamethasone therapy compared to placebo in adults with acute bacterial meningitis.
• To assess the impact of dexamethasone on patient outcomes, including mortality and neurological function.

Main Methods:

• A prospective, randomized, double-blind, multicenter trial involving 301 adult patients with acute bacterial meningitis.
• Dexamethasone (10 mg) or placebo was administered before or with the first antibiotic dose and continued every 6 hours for four days.
• Primary outcome was the Glasgow Outcome Scale score at eight weeks; subgroup analysis by causative organism was performed.

Main Results:

• Dexamethasone treatment significantly reduced the risk of unfavorable outcomes (relative risk, 0.59; P=0.03) and mortality (relative risk, 0.48; P=0.04).
• In pneumococcal meningitis cases, dexamethasone halved the rate of unfavorable outcomes (26% vs. 52%; P=0.006).
• Gastrointestinal bleeding rates were low and similar between the dexamethasone (2 patients) and placebo (5 patients) groups.

Conclusions:

• Early administration of dexamethasone as adjuvant therapy improves clinical outcomes in adults with acute bacterial meningitis.
• Dexamethasone treatment does not elevate the risk of gastrointestinal bleeding in this patient population.
• The findings support the use of dexamethasone for acute bacterial meningitis to reduce mortality and improve patient prognoses.